Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Grail Inc.
Contrasting first-quarter preannouncements from a DNA sequencing company and a molecular diagnostics company may, with other seasonal pressures, imply a comparatively weak first quarter for therapeutic drug companies.
Illumina announced plans to acquire Grail for about $8bn in September 2020, but the US FTC says the proposed acquisition will diminish innovation in the US market for multi-cancer testing.
SUMMIT, the landmark study conducted within the UK focused on diagnosing lung cancer before it becomes untreatable, has demonstrated the practicality and cost effectiveness of mass CT screening.
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the first day of the meeting.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- GRAILBio Cirina Ltd